Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
Daxor Corporation (NYSE: DXR) will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on October 13, 2020, at 3:00 PM ET. President and CEO Michael Feldschuh will provide insights on the company, including recent research from the Heart Failure Society of America, highlighting the BVA-100® blood test's cost-effectiveness and its potential to enhance patient lifespan in heart failure.
A Q&A session will follow the presentation. For more details, visit microcaprodeo.com.
- None.
- None.
NEW YORK, NY, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on Tuesday, October 13th at 3:00 PM ET.
Mr. Feldschuh will provide a company overview and discuss key highlights including new research recently presented at the Heart Failure Society of American Virtual Annual Scientific Meeting 2020 on the cost- effectiveness and improvement in patient life-span using Daxor’s BVA-100® blood test in heart failure. A Q&A session will follow after the webcast.
Event Details
Webcast: Tuesday, October 13th, 2020
Time: 3:00 PM Eastern Time
Link: https://www.webcaster4.com/Webcast/Page/2134/37954
To receive additional information, request an invitation or to schedule a one-on-one meeting, please visit https://microcaprodeo.com.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
FAQ
What is the date and time of Daxor's presentation at the MicroCap Rodeo Best Ideas Bowl?
Who will present on behalf of Daxor Corporation at the event?
What key highlights will be discussed during Daxor's presentation?
Is there a Q&A session planned after Daxor's presentation?
How can I access the webcast of Daxor's presentation?
What is Daxor's main focus in the medical field?
